Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
33.58
+1.91 (6.03%)
At close: Apr 2, 2026, 4:00 PM EDT
33.08
-0.50 (-1.49%)
After-hours: Apr 2, 2026, 7:42 PM EDT

Rapport Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Selling, General & Admin
30.3122.128.18
Research & Development
94.7960.9428
Total Operating Expenses
125.183.0636.18
Operating Income
-125.1-83.06-36.18
Interest Income
13.6212.142.53
Other Non-Operating Income (Expense)
--7.39-1.12
Total Non-Operating Income (Expense)
13.624.751.4
Pretax Income
-111.48-78.31-34.78
Provision for Income Taxes
--0.01
Net Income
-111.48-78.31-34.79
Net Income to Common
-111.48-78.31-34.79
Shares Outstanding (Basic)
39212
Shares Outstanding (Diluted)
39212
Shares Change (YoY)
87.74%1277.25%-
EPS (Basic)
-2.86-3.78-23.10
EPS (Diluted)
-2.86-3.78-23.10
Shares Outstanding
47.7736.584.17
Free Cash Flow
-88.09-67.23-28.82
Free Cash Flow Per Share
-2.26-3.24-19.14
EBITDA
-124.08-82.22-36.07
EBIT
-125.1-83.06-36.18
Effective Tax Rate
0.00%0.00%-0.03%
Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q